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Introduction
Daily oral preventive therapies for frequent and/or dis-
abling migraine attacks are fraught with possible adverse
effects and drug-drug interactions. Curative therapy is
non-existent.
Sensitisation of peripheral and central nociceptors are
common mechanisms contributing to the development of
chronic pain and, along with other morphological changes
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Abstract Chronic migraine manage-
ment almost always requires daily oral
preventative medication with potential
adverse effects. Daily oral preventa-
tive therapy may also not be effective
in terminating chronic migraine.
Chronic central sensitisation caused
by repetitive migraine attacks in a
young person may lower the threshold
for future migraine episodes leading to
an intractable and debilitating disease
course. The objective was to deter-
mine if short-term parenteral dihy-
droergotamine, dexamethasone and
hydroxyzine can terminate chronic
migraine and be followed by a contin-
uous respite or conversion to a more
benign episodic form without the need
for daily oral preventative medication
(“carry-over effect”). We treated ten
patients, seven adolescents and three
adults, with parenteral dihydroergota-
mine, dexamethasone and hydrox-
yzine given once a week for a maxi-
mum of three weeks. No oral preven-
tative daily medication was adminis-
tered. The setting was a private prac-
tice. Chronic migraine was terminated
in all 7 adolescents. Their post-treat-
ment course was converted to a more
benign episodic migraine course and
no adolescent required daily oral
migraine preventative therapy for sig-
nificantly long carry-over post-treat-
ment observational periods. None of
the three adult chronic migraine cases
could be terminated satisfactorily as
they all required daily oral preventa-
tive therapy. In the adolescent group
only, this strategy terminated chronic
migraine and resulted in a significant
carry-over effect that appeared to
favourably modify the long-term
course without the need for daily
pharmacological, potentially toxic,
preventive therapy. Although this is a
very small study, which requires con-
firmation by a larger controlled study,
our data suggest a significant carry-
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of the brainstem, may be operative in chronic headache
syndromes [1, 2]. Chronic central sensitisation caused by
repetitive uncontrolled severe migraine attacks in a young
person might lower the threshold for future attacks ulti-
mately leading to an intractable, treatment-resistant
malignant disease course in adult life. Burstein suggested
that with repeated migraine attacks over the years, there is
an increased likelihood that the patient will exhibit allo-
dynia, thereby experiencing attacks at a higher frequency.
Such age-related progression of the disease can become a
growing obstacle for migraine treatment [3].
A desirable short-term therapy designed to dampen or
extinguish the multiple migraine brain generator sites
thought to be present in the brainstem would prevent
chronic sensitisation from occurring [4]. This novel
approach to migraine would result in a carry-over effect,
decrease frequent debilitating headache attacks and
decrease the need for daily preventive medications with
all their potential adverse events. It would also decrease
acute care and rescue medications and emergency room
visits. It would probably result in large cost savings.
The “carry-over effect” is cessation of what has been a
clinically effective course of therapy followed by a pro-
longed period of continued relief from pervasive headache
without continuance of such therapy. In one study of
transformed migraine, only 8 out of 20 patients obtained a
sustained carry-over effect only two months following
cessation of divalproex sodium prophylactic therapy [5].
Rapoport devised a protocol administering dihydroer-
gotamine 1 mg IM or IV; dexamethasone 4 mg IM or IV;
and either promethazine 50 mg IM or metoclopramide 10
mg IM or IV in patients who appeared to be entering into
or were in the midst of status migrainosus [6]. Acute care
therapy with intramuscular dihydroergotamine has been
used safely and successfully in the office setting [7]. It is
frequently used intravenously on a repetitive basis for
patients with chronic headache who have been hospi-
talised for treatment [8].
Patients and methods
Our 10 patients initially presented to the office with severe pro-
longed headache or in status migrainosus. They were given a
choice of receiving treatment with the Rapoport protocol or
receiving conventional outpatient abortive, rescue and preven-
tative oral medications. Patients who desired or needed rapid
parenteral relief and did not want daily preventative medication
were treated with outpatient intramuscular dihydroergotamine
0.5–1 mg, dexamethasone 8–12 mg and hydroxyzine 50 mg
(DHE/DEX/HYD) given in three separate injection sites.
Hydroxyzine was substituted for promethazine or metoclo-
pramide because of its marked sleep inducing properties, which
was felt to be beneficial in breaking the chronic migraine cycle,
and to minimise the chances of acute dystonic reactions. All
patients met the new IHS criteria for chronic migraine (without
analgesic overuse). Pretreatment parameters that were recorded
were the number of headache episodes per month, and the aver-
age intensity of each headache using a numeric pain scale (NPS)
of 1–10; a 1 level was rated as the mildest headache and a 10
level was the worst headache of one’s life (Table 1). All had
normal neurological examinations, brain MRI scans, laboratory
investigations and had no other health problems. Except for
mild to moderate pain from the hydroxyzine injection, no other
adverse effects were reported. Within 30 min of treatment, vir-
tually all patients fell asleep for several hours. Treatments were
administered 1–3 times, separated by 1 week intervals depend-
ing upon clinical response and/or patient preference. No patient
was placed on daily pharmacological preventative treatment.
Abortive treatment with either a triptan or analgesic was per-
mitted.
Results
All 7 of the adolescents experienced satisfactory abortive
relief with significant sustained decrease in frequency and
pain intensity for periods of post-treatment observation
that ranged from 6 months to 4 years. The 3 adults did not
convert to a less debilitating headache course (Table 2).
Case 2 was satisfied taking a prn triptan 8 times a month
without any loss of school or social activity, triptan
adverse effects or triptan rebound. Two of the adults
(cases 9 and 10) whose chronic migraine could not be ter-
minated with the DHE/DEX/HYD treatments, required
daily pharmacological preventative therapy. Adult patient,
case no. 8, required inpatient IV DHE followed by daily
Table 1 Pre-treatment frequency and intensity of headache
Case Monthly frequency NPS*
1. 14 y/oF 15 9/10
2. 15 y/oF Daily 10/10
3. 15 y/oF 22 8/10
8 10/10
4. 15 y/oF 16 10/10
5. 15 y/oF 10 5/10
12 10/10
6. 16 y/oF 12 5/10
7. 17 y/oF 26 6/10
4 10/10
8. 21 y/oF 20 8/10
9. 23 y/oM 26 5/10
4 10/10
10. 31 y/oF Daily 10/10
*1/10 mildest headache………….10/10 worst headache ever
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pharmacological preventative treatment. The adolescent
group demonstrated a significant carry-over effect. The 3
adults did not obtain a carry-over effect.
Conclusions
All of the 7 adolescents with chronic migraine that were
treated with 1–3 treatments of IM DHE/DEX/HYD clear-
ly were converted to a benign or improved post-treatment
headache course without requiring daily oral preventative
therapy. A carry-over effect occurred only in these young
migraineurs. A carry-over effect did not occur in the 3
adult cases and they required daily pharmacological ther-
apy for headache management.
Loder, in a recent review of disease modification of
migraine, raised the question, “Who will benefit?” [9].
Although our study cannot infer disease modification, our
favourable clinical results suggest it is the adolescent with
chronic migraine who might benefit. The combination of
IM DHE/DEX/HYD in producing an excellent carry-over
effect and the failure to do so in the adult may be due to
the fact that in the adult, central sensitisation has already
become well established so that a successful carry-over
effect is physiologically impossible.
HYD probably induces sleep by blocking cholinergic
neurons in the pontine tegmentum modifying serotonergic
sleep raphe nuclei and also by blocking histamine release.
DHE is a known 5HT1 receptor agonist. Dexamethasone
inhibits neurogenic inflammation.
Magnoux was able to induce a remission of the chron-
ic form of refractory cluster headache and transform it to
the episodic form [10]. We accomplished analogous results
with our adolescent chronic migraine series, but our study
is obviously limited by the small number of patients. In the
young migraineur, IM DHE/DEX/HYD attenuated pro-
longed or frequent headache probably by preventing the
establishment of central sensitisation through suppression
of multiple migraine brain generator sites. The small num-
ber of adolescents treated with IM DHE/DEX/HYD had a
significant carry-over effect without exposure to the poten-
tial drug toxicity from daily prophylactic migraine therapy.
A larger randomised trial, possibly with outpatient intra-
venous DHE and steroids, needs to be conducted before
more definitive conclusions can be drawn.
Table 2 Post-treatment patient characteristics
Case No. of treatments* Monthly frequency NPS Post-treatment observation**
1. 14 y/oF 1 1 3/10 2 years
2. 15 y/oF 3 8 7/10 6 months
3. 15 y/oF 1 1 2/10 4 years
4. 15 y/oF 3 2 2/10 6 months
5. 15 y/oF 3 4 3/10 6 months
6. 16 y/oF 2 1 2/10 4 years
7. 17 y/oF 2 2 6/10 1 year
8. 21 y/oF 1 20 9/10 5 days
9. 23 y/oM 2 26 5/10 1 month
4 10/10
10. 31 y/oF 3 Daily 10/10 2 weeks
*Treatment consisted of DHE 0.5–1 mg IM, DEX 8–12 mg IM and HYD 25–50 mg IM given at weekly intervals
**Patients 1–7 period of clinical follow-up during which no patient relapsed back to pretreatment status. Patients 8–10 did not respond or
were severely disabled requiring alternative/urgent treatment
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